InvestorsHub Logo
Post# of 251720
Next 10
Followers 36
Posts 2620
Boards Moderated 0
Alias Born 10/06/2003

Re: None

Thursday, 12/02/2010 4:03:03 PM

Thursday, December 02, 2010 4:03:03 PM

Post# of 251720
http://finance.yahoo.com/news/Teva-Comments-on-Patent-bw-2437340711.html?x=0&.v=1

Press Release Source: Teva Pharmaceutical Industries Ltd. On Thursday December 2, 2010, 3:55 pm
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA - News) commented today on the patent infringement lawsuit filed by Momenta Pharmaceuticals, Inc. and Sandoz Inc.

Teva received a copy of the complaint which claims that the manufacture of its generic Lovenox® (enoxaparin sodium) injection, which is still under active review at U.S. Food and Drug Administration, has infringed Momenta's U.S. Patent Nos. 7,575,886 (the "'886 patent") and 7,790,466 (the "'466 patent"), and will infringe those patents once it is officially approved and marketed in the United States. Teva's version of generic Lovenox, which is manufactured and tested outside of the U.S., does not infringe either of these patents. Teva believes that this lawsuit is without merit, and Teva intends to seek reimbursement for all legal fees in fighting these baseless allegations.

smile

ij

There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.